prx08066
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2006 (NCT00345774)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 5-((4-(6-chlorothieno(2,3-d)pyrimidin-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile
- prx08066
- prx 08066
- prx-08066
- prx-08066
- prx-08066
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00677872 | Phase 2 | May 1, 2008 | Epix Pharmaceuticals |
| NCT00345774 | Phase 2 | Jun 1, 2006 | Epix Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Epix Pharmaceuticals | For profit | 2 | 2 | 1 | 2006 |
1 organizations
Page 1 / 1